Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

16.60
+0.73004.60%
Post-market: 16.900.3000+1.81%18:51 EDT
Volume:2.41M
Turnover:39.30M
Market Cap:1.97B
PE:-14.34
High:16.85
Open:16.03
Low:15.70
Close:15.87
Loading ...

BRIEF-Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
07 Jan

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 Jan

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

Zacks
·
04 Jan

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Simply Wall St.
·
02 Jan

HC Wainwright Initiates Arcutis Biotherapeutics at Buy With $19 Price Target

MT Newswires Live
·
30 Dec 2024

U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent

Reuters
·
30 Dec 2024

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Zacks
·
26 Dec 2024

Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)

TIPRANKS
·
25 Dec 2024

Arcutis Biotherapeutics Soars on Zoryve Success and Bullish Analyst Ratings

TIPRANKS
·
18 Dec 2024

Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA for Zoryve Cream

MT Newswires Live
·
16 Dec 2024

Arcutis Submits Zoryve® (Roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis

THOMSON REUTERS
·
16 Dec 2024

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Warby Parker (WRBY)

TIPRANKS
·
16 Dec 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 Dec 2024

Arcutis Biotherapeutics announces promotions on executive management team

TIPRANKS
·
03 Dec 2024

Arcutis Announces Promotions on Executive Management Team

THOMSON REUTERS
·
03 Dec 2024

Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy?

Zacks
·
27 Nov 2024